The use of stereotactic body radiotherapy (SABR) prior to pembrolizumab in patients with metastatic NSCLC has demonstrated improved PFS and OS in the PD-L1-negative subgroup [57]. Here, CD274 is linked to non-small cell lung carcinoma.